Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An announcement from Nutriband ( (NTRB) ) is now available.
On December 29, 2025, Nutriband Inc. announced that it has signed an agreement to sell a 90% stake in its subsidiary Pocono Pharmaceutical to EarthVision Bio for $5 million, with closing expected on December 31, 2025. Following the transaction, Nutriband shareholders will retain a 10% shareholding in EarthVision Bio, which is commercializing a new category of sustainable alternatives to plastic, molded fiber, wood and paper products developed by Intel founder Dr. Gordon Moore and former Chevron Europe chairman Dr. Hans Franke. Nutriband plans to use the sale proceeds to advance development of AVERSA Fentanyl, which it positions as a potential first-in-class abuse-deterrent opioid patch with an estimated U.S. annual sales opportunity of $80 million to $200 million, signaling a strategic capital redeployment toward its core transdermal drug-delivery platform and lead product candidate.
The most recent analyst rating on (NTRB) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Nutriband stock, see the NTRB Stock Forecast page.
Spark’s Take on NTRB Stock
According to Spark, TipRanks’ AI Analyst, NTRB is a Neutral.
Nutriband’s overall stock score is driven by a strong corporate event with positive market reception, offset by challenging financial performance and valuation issues. The technical analysis provides mixed signals, suggesting cautious optimism. The potential for shareholder value enhancement through recent corporate actions improves the score despite underlying financial weaknesses.
To see Spark’s full report on NTRB stock, click here.
More about Nutriband
Nutriband Inc., based in Orlando, is primarily engaged in developing a portfolio of transdermal pharmaceutical products, with a lead focus on an abuse-deterrent fentanyl patch that incorporates its proprietary AVERSA abuse-deterrent transdermal technology. AVERSA is designed to be integrated into any transdermal patch to reduce abuse, misuse, diversion and accidental exposure of drugs with abuse potential, and is protected by a broad international patent portfolio spanning the United States, Europe, Japan, Korea, Russia, China, Canada, Mexico and Australia.
Average Trading Volume: 42,749
Technical Sentiment Signal: Sell
Current Market Cap: $67.81M
See more insights into NTRB stock on TipRanks’ Stock Analysis page.